China Medical System says China approves rabies antibody drug Silevimig InjectionPUBT·Jun 22 at 04:31 AM8A8-5.74%00867-0.58%
The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suitWallstreetcn·Jan 8 at 11:26 PM300878-1.36%688221-2.47%
Genrix Bio signed a commercialization cooperation agreement for Weikang Duta monoclonal antibody injection and Sileweimi monoclonal antibody injectionZhitong·Sep 22, 2025 at 06:42 AM688443+0.52%00867-0.58%
Genrix Bio's clinical trial application for the research product GR2301 injection has been approvedZhitong·Sep 17, 2025 at 03:48 AM688443+0.52%
Genrix Bio: The new drug application for Talikizumab injection has been acceptedZhitong·Sep 11, 2025 at 04:08 AM688443+0.52%
Genrix Bio: GR1803 injection system for systemic lupus erythematosus indication approved for clinical trialsZhitong·Sep 10, 2025 at 04:53 AM688443+0.52%
Genrix Bio: GR2303 injection has obtained the drug clinical trial approval noticeZhitong·Sep 8, 2025 at 03:48 AM688443+0.52%
Genrix Bio: GR1802 injection for adolescent seasonal allergic rhinitis indication has received clinical trial approvalZhitong·Aug 19, 2025 at 04:38 AM688443+0.52%
Genrix Bio: GR1802 injection initiates Phase III clinical trial for allergic rhinitis indicationZhitong·Aug 13, 2025 at 03:24 AM688443+0.52%
Genrix Bio: SLEW-MAB injection has received approval for clinical trialsZhitong·Jul 29, 2025 at 03:41 AM688443+0.52%
Genrix Bio: GR1803 injection has obtained the drug clinical trial approval noticeZhitong·Jul 2, 2025 at 04:54 AM688443+0.52%
Genrix Bio signed a licensing and commercialization agreement with Cullinan for the GR1803 injectionZhitong·Jun 4, 2025 at 07:16 PM688443+0.52%
Genrix Bio: The new drug application for GR2001 injection has been acceptedZhitong·May 22, 2025 at 04:49 AM688443+0.52%
Genrix Bio released its first-quarter performance, with a net loss attributable to the parent company of 121 million yuan, narrowing the lossZhitong·Apr 25, 2025 at 09:56 AM688443+0.52%
